David R. Spriggs - Concepedia

Author

David R. Spriggs

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

D R Spriggs, D SPRIGGS, D Spriggs, D. R. Spriggs, D. SPRIGGS, D. Spriggs, D.R. SPRIGGS, D.R. Spriggs, DAVID R. SPRIGGS, DAVID SPRIGGS

425

Publications

17.3K

Citations

H-Index

181

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute Harvard University Cornell University The University of Texas MD Anderson Cancer Center

About

David R. Spriggs is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	51	92	9.1K
2	Health Sciences	14	16	1.3K
3	Engineering	3	3	501
4	Arts	1	1	29
5	Education	1	1	29

David R. Spriggs

169

Publications

16.5K

Citations

H-Index

Page 1

	Year	Citations
Detection of Circulating Tumor Necrosis Factor after Endotoxin Administration H. R. Michie, Kirk R. Manogue, David R. Spriggs, New England Journal of Medicine ImmunologyPathologyInflammationBiomarker (Medicine)Translational Medicine	1988	1.7K
Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial Martee L. Hensley, Robert G. Maki, Ennapadam Venkatraman, Journal of Clinical Oncology Unresectable LeiomyosarcomaSurgical OncologyPhase Ii TrialRadiation TherapyMedicine	2002	684
Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Dennis E. Hallahan, David R. Spriggs, Michael A. Beckett, Proceedings of the National Academy of Sciences EngineeringRadiation EffectImmunologyRadiation ExposurePathology	1989	466
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Carol Aghajanian, Steven L. Soignet, Don S. Dizon, PubMed	2002	456
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors <i>in vivo</i> Mythili Koneru, Terence J. Purdon, David R. Spriggs, OncoImmunology	2015	406
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment Oladapo Yeku, Terence J. Purdon, Mythili Koneru, Scientific Reports	2017	386
Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings H. R. Michie, David R. Spriggs, Kirk R. Manogue, Journal of Critical Care InflammationMetabolic SyndromeTumor Necrosis FactorEnergy MetabolismPhysiology	1989	362
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer Mythili Koneru, Roisin E. O’Cearbhaill, Swati Pendharkar, Journal of Translational Medicine	2015	310
Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients Paul Sabbatini, Takemasa Tsuji, Luis Ferran, Clinical Cancer Research	2012	272
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma Robert A. Soslow, Guangming Han, Kay J. Park, Modern Pathology Tumoral PathologyCancer PathologyTumor HeterogeneityMedicineGenetics	2011	258

Page 1